Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab

Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab

Abstract A 52‐year‐old man underwent pneumonectomy of the left lung for previously diagnosed primary spindle cell carcinoma (pT4aN1M0, stage III B) with programmed death‐ligand 1 expression (tumor proportion score ≥95%) and without epidermal growth factor receptor gene mutation and anaplastic lympho...

Full description

Bibliographic Details
Main Authors: Yoshiko Mizushina, Fumiyoshi Ohyanagi, Jun Shiihara, Motoko Nomura, Hiromitsu Ohta, Hisashi Oshiro, Hiroyoshi Tsubochi, Gen Kusaka, Yasuhiro Yamaguchi
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Thoracic Cancer
Subjects:
immune checkpoint inhibitor
lung cancer
pembrolizumab
pseudoprogression
spindle cell carcinoma
Online Access:https://doi.org/10.1111/1759-7714.14068

Internet

https://doi.org/10.1111/1759-7714.14068

Similar Items